{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:22Z","timestamp":1790874742130,"version":"4.1.0"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"8","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0179_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Myositis specific antibodies (MSA) are important in the diagnosis of idiopathic inflammatory myopathies (IIM). In addition, several studies have shown clear utility to stratify IIM patients into more homogeneous subsets based on MSA signatures. However, methods for MSA detection show various degrees of agreement. Here, we aim to compare novel methods for the detection of\u00a0MSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0179_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MSA were measured in 122 samples using the novel Autoimmune Myopathy reagents employing particle-based multi-analyte technology (PMAT) and compared with ELISA for anti-Mi-2, anti-MDA5, and anti-TIF1-\u03b3 antibody detection. Data for line immunoassay was available for 49 samples. Preliminary research thresholds were applied to the assays to calculate MSA prevalence in the sample populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0179_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparison of PMAT and ELISA for anti-Mi-2, anti-MDA5, and anti-TIF1-\u03b3 antibodies revealed high agreement across all three analytes: Kappa agreements between the two methods were 1.00 (95\u202f% CI 1.00\u20131.00) for anti-Mi-2, 0.89 (95\u202f% CI 0.66\u20131.00) for anti-MDA5 and 0.84 (95\u202f% CI 0.67\u20131.00) for anti-TIF1-\u03b3. Quantitative agreements were: Anti-Mi-2 r=0.56 (95\u202f% CI 0.42\u20130.67), anti-MDA5 r=0.42 (95\u202f% CI 0.25\u20130.56) and anti-TIF1-\u03b3=0.45 (95\u202f% CI 0.30\u20130.59). ROC analysis demonstrated excellent discrimination of ELISA positive and negative samples using PMAT, with AUC values of 1.00 for anti-Mi-2, anti-TIF1-\u03b3, and 0.99 for anti-MDA5 antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0179_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data showed high agreement between PMAT and ELISA for three important MSA, providing further evidence of the utility of such methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0179","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:57:22Z","timestamp":1778774242000},"page":"1817-1825","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive assessment of innovative immunoassays for the detection of myositis specific antibodies"],"prefix":"10.1515","volume":"64","author":[{"given":"Ivo","family":"Rimann-Langejuergen","sequence":"first","affiliation":[{"name":"Exagen Inc , Vista , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Silva","sequence":"additional","affiliation":[{"name":"Exagen Inc , Vista , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"Exagen Inc , Vista , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Bentow","sequence":"additional","affiliation":[{"name":"Werfen Autoimmunity Technology Center, Autoimmunity , San Diego , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mahler","sequence":"additional","affiliation":[{"name":"Exagen Inc , Vista , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026070213034372388_j_cclm-2026-0179_ref_001","doi-asserted-by":"crossref","unstructured":"McHugh, NJ, Tansley, SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018;14:290\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2018.56.","DOI":"10.1038\/nrrheum.2018.56"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_002","doi-asserted-by":"crossref","unstructured":"Lundberg, IE, Tj\u00e4rnlund, A, Bottai, M, Werth, VP, Pilkington, C, De Visser, M, et al.. 2017 European Lague Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017;69:2271\u201382, https:\/\/doi.org\/10.1002\/art.40320.","DOI":"10.1136\/annrheumdis-2017-212786"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_003","doi-asserted-by":"crossref","unstructured":"Casta\u00f1eda, S, Cavagna, L, Gonz\u00e1lez-Gay, MA. Consideration of antisynthetase syndrome features in classifying patients as having idiopathic inflammatory Myopathy: comment on the article by Lundberg et\u00a0al. Arthritis Rheumatol 2018;70:975\u20136. https:\/\/doi.org\/10.1002\/art.40478.","DOI":"10.1002\/art.40478"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_004","doi-asserted-by":"crossref","unstructured":"Malaviya, AN. 2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why? Ann Rheum Dis 2018;77:e77. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212701.","DOI":"10.1136\/annrheumdis-2017-212701"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_005","doi-asserted-by":"crossref","unstructured":"Palterer, B, Vitiello, G, Carraresi, A, Giudizi, MG, Cammelli, D, Parronchi, P, et al.. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy 2018;16:5. https:\/\/doi.org\/10.1186\/s12948-018-0084-9.","DOI":"10.1186\/s12948-018-0084-9"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_006","doi-asserted-by":"crossref","unstructured":"Tansley, SL, Snowball, J, Pauling, JD, Lissina, A, Kuwana, M, Rider, LG, et al.. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Res Ther 2020;22:117. https:\/\/doi.org\/10.1186\/s13075-020-02210-2.","DOI":"10.1186\/s13075-020-02210-2"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_007","doi-asserted-by":"crossref","unstructured":"Piette, Y, De Sloovere, M, Vandendriessche, S, Dehoorne, J, De Bleecker, JL, Van Praet, L, et al.. Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy. Clin Exp Rheumatol 2020;38:212\u20139. https:\/\/doi.org\/10.55563\/clinexprheumatol\/3cuc1s.","DOI":"10.55563\/clinexprheumatol\/3cuc1s"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_008","doi-asserted-by":"crossref","unstructured":"Lackner, A, Tiefenthaler, V, Mirzayeva, J, Posch, F, Rossmann, C, Kastrati, K, et al.. The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study. Ther Adv Musculoskelet Dis 2020;12:1759720x20975907. https:\/\/doi.org\/10.1177\/1759720x20975907.","DOI":"10.1177\/1759720X20975907"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_009","doi-asserted-by":"crossref","unstructured":"Loganathan, A, Gupta, L, Rudge, A, Lu, H, Bowler, E, McMorrow, F, et al.. Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort. Rheumatology 2024;63:2363\u201371. https:\/\/doi.org\/10.1093\/rheumatology\/keae167.","DOI":"10.1093\/rheumatology\/keae167"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_010","doi-asserted-by":"crossref","unstructured":"Mecoli, CA, Albayda, J, Tiniakou, E, Paik, JJ, Zahid, U, Danoff, SK, et al.. Myositis autoantibodies: a comparison of results from the oklahoma medical research foundation myositis panel to the euroimmun research line blot. Arthritis Rheumatol 2020;72:192\u20134. https:\/\/doi.org\/10.1002\/art.41088.","DOI":"10.1002\/art.41088"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_011","doi-asserted-by":"crossref","unstructured":"Gono, T, Gil-Vila, A, Selva-O\u2019Callaghan, A, van Royen-Kerkhof, A, Vincze, A, Mecoli, C, et al.. Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: a systematic review and meta-analysis. Semin Arthritis Rheum 2025;75:152858. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152858.","DOI":"10.1016\/j.semarthrit.2025.152858"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_012","doi-asserted-by":"crossref","unstructured":"Mahler, M, Betteridge, Z, Bentow, C, Richards, M, Seaman, A, Chinoy, H, et al.. Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol 2019;10:848. https:\/\/doi.org\/10.3389\/fimmu.2019.00848.","DOI":"10.3389\/fimmu.2019.00848"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_013","doi-asserted-by":"crossref","unstructured":"Mahler, M, Malyavantham, K, Seaman, A, Bentow, C, Anunciacion-Llunell, A, Sanz-Martinez, MT, et al.. Profiling of Myositis specific antibodies and composite scores as an aid in the differential diagnosis of autoimmune myopathies. Diagnostics 2021;11. https:\/\/doi.org\/10.3390\/diagnostics11122246.","DOI":"10.3390\/diagnostics11122246"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_014","doi-asserted-by":"crossref","unstructured":"Ghirardello, A, Gatto, M, Franco, C, Zanatta, E, Padoan, R, Ienna, L, et al.. Detection of Myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies. Diagnostics 2023;13. https:\/\/doi.org\/10.3390\/diagnostics13193080.","DOI":"10.3390\/diagnostics13193080"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_015","doi-asserted-by":"crossref","unstructured":"Mulhearn, B, Li, D, McMorrow, F, Lu, H, McHugh, NJ, Tansley, SL. A commercial Anti-TIF1\u03b3 ELISA is superior to line and dot blot and should be considered as part of routine Myositis-specific antibody testing. Front Immunol 2022;13:804037. https:\/\/doi.org\/10.3389\/fimmu.2022.804037.","DOI":"10.3389\/fimmu.2022.804037"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_016","doi-asserted-by":"crossref","unstructured":"Pinto Oliveira, C, Pereira Silva, M, Vilafanha, C, Costa, G, Santos, ME, Gon\u00e7alves, MJ, et al.. Impact of concordance between antinuclear antibody indirect immunofluorescence patterns and myositis antibodies in idiopathic inflammatory myopathies: study protocol. Acta Med Port 2025;38:718\u201323. https:\/\/doi.org\/10.20344\/amp.23542.","DOI":"10.20344\/amp.23542"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_017","doi-asserted-by":"crossref","unstructured":"Richards, M, Garc\u00eda-De La Torre, I, Gonz\u00e1lez-Bello, YC,\u00a0V\u00e1zquez-Del Mercado, M, Andrade-Ortega, L, Medrano-Ram\u00edrez, G, et al.. Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology 2019;58:1655\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kez092.","DOI":"10.1093\/rheumatology\/kez092"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_018","doi-asserted-by":"crossref","unstructured":"Mahler, M, Vulsteke, JB, Bossuyt, X, De Langhe, E, Satoh, M. Standardisation of myositis-specific antibodies: where are we today? Ann Rheum Dis 2021;80:e132. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216003.","DOI":"10.1136\/annrheumdis-2019-216003"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_023","doi-asserted-by":"crossref","unstructured":"Wang, R, Lin, W, Xie, Q, Yin, G. Targeted therapy for idiopathic inflammatory myopathy. J\u00a0Cachexia Sarcopenia Muscle 2025;16:e70143. https:\/\/doi.org\/10.1002\/jcsm.70143.","DOI":"10.1002\/jcsm.70143"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_019","doi-asserted-by":"crossref","unstructured":"Pinal-Fernandez, I, Pak, K, Casal-Dominguez, M, Hosono, Y, Mecoli, C, Christopher-Stine, L, et al.. Validation of anti-Mi2 autoantibody testing by line blot. Autoimmun Rev 2020;19:102425. https:\/\/doi.org\/10.1016\/j.autrev.2019.102425.","DOI":"10.1016\/j.autrev.2019.102425"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_020","doi-asserted-by":"crossref","unstructured":"Cavazzana, I, Richards, M, Bentow, C, Seaman, A, Fredi, M, Giudizi, MG, et al.. Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. J\u00a0Immunol Methods 2019;474:112661. https:\/\/doi.org\/10.1016\/j.jim.2019.112661.","DOI":"10.1016\/j.jim.2019.112661"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_021","doi-asserted-by":"crossref","unstructured":"Pinal-Fernandez, I, Musai, J, Casal-Dominguez, M, Pak, K, Kaplan, M, Warner, BM, et al.. Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1\u03b3, while anti-TIF1\u03b3 autoantibodies primarily bind TIF1\u03b3 outside the PHD region. Rheumatology 2025;64:6371\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keaf426.","DOI":"10.1093\/rheumatology\/keaf426"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_022","doi-asserted-by":"crossref","unstructured":"Gallay, L, Alhassan, E, Bhowmick, N, Aggarwal, R. Emerging therapies in idiopathic inflammatory myopathies: advances in treatment and future directions. Best Pract Res Clin Rheumatol 2025;39:102107. https:\/\/doi.org\/10.1016\/j.berh.2025.102107.","DOI":"10.1016\/j.berh.2025.102107"},{"key":"2026070213034372388_j_cclm-2026-0179_ref_024","doi-asserted-by":"crossref","unstructured":"Chen, Z, Wang, H, Wu, W, Fu, Y, Xu, W, Zhang, D, et al.. Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease. Respir Res 2026;27:142.","DOI":"10.1186\/s12931-026-03572-y"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0179\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:14:33Z","timestamp":1783005273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0179\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1515\/cclm-2026-0179"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0179","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}